{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-007741","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.492931+00:00","generated_at":"2026-06-28T11:07:28.944019+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Celldex reports Q3 net loss of $20.5M, cash $423M, CDX-0159 95% complete response.","bullets":["Net loss $20.5M ($0.45/share) in Q3 2021; revenue $0.2M, vs net loss $14.2M ($0.36/share) in Q3 2020.","Cash, cash equivalents & marketable securities $423.1M at Sept 30, 2021, up from $164M at June 30; cash runway through 2025.","CDX-0159 Phase 1b in inducible urticaria: 95% complete response (18/19) after single dose; median response duration 77+ days (cold urticaria) and 57+ days (symptomatic dermographism).","Completed $287.5M gross public offering in July 2021; net proceeds $269.9M.","CDX-1140 combo with pembrolizumab shows confirmed partial response in head and neck cancer; ovarian expansion enrolling for CDX-527."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-007741","json":"https://secwatch.observer/filing/0001171843-21-007741.json","markdown":"https://secwatch.observer/filing/0001171843-21-007741.md","text":"https://secwatch.observer/filing/0001171843-21-007741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184321007741/0001171843-21-007741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184321007741/f8k_110921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:07:28.944019+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}